ArticleHuman vaccines & immunotherapeutics2025
Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in Hong Kong - A retrospective database study.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is limited information on the association between burden of pneumococcal disease and vaccination. This study aimed to assess pneumococcal disease burden among adults in Hong Kong by estimating incidence rate (IR), case fatality rate (CFR), healthcare resource utilization and costs before and after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into Hong Kong's childhood immunization program (CIP) in 2011. Adults ≥18 years hospitalized with invasive pneumococcal disease (IPD) and pneumonia from 2005 to 2019 were identified from the Clinical Data Analysis and Reporting System (CDARS). Interrupted time series analysis (ITSA) was performed and incidence rate ratio (IRR) was computed to compare baseline and trend of IRs between pre-introduction (2005-2010) and post-introduction (2012-2019) of PCV13. Overall IPD and pneumonia IRs were 0.78 and 5.34 episodes per 100,000 person-years, respectively. ITSA showed no changes in baseline IPD IR (IRR = 0.82;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.